seeking biotech alpha April 2019 insight

BriaCell Therapeutics (BCTXF) and Incyte (INCY)

image152

BriaCell Announces Clinical Trial Collaboration Agreement with Incyte

Tue April 2, 2019 2:58 PM|GlobeNewswire|About: BCTXF, INCY, MRK

  • BriaCell Therapeutics (BCTXF) and Incyte (INCY) have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates
  • Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA0012, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients

BERKELEY, Calif., and VANCOUVER, British Columbia, April 02, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF),

Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration

image153

 Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms

Wed April 3, 2019 7:00 AM|GlobeNewswire|About: EDIT

– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology –

– Collaboration enables Editas Medicine (EDIT) to discover and develop engineered cell medicines across oncology, including solid tumors and blood cancers –

CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.,


 http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-and-bluerock-therapeutics-enter-strategic 


 https://bluerocktx.com/  

Fasenra (benralizumab)

image156

AstraZeneca's Fasenra successful in mid-stage HES study

Apr. 4, 2019 7:21 AM ET|About: AstraZeneca PLC (AZN)|By: , SA News Editor  


 https://www.fasenra.com/ 

seeking biotech alpha April 2019 insight

intratumoral TLR9 agonist SD-101 induced a systemic anti-tumoral immune response

image158

Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models

Mon April 1, 2019 1:00 PM|GlobeNewswire|About: DVAX

BERKELEY, Calif. and PLANEGG-MARTINSRIED, Germany, April 01, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX)

Amgen Inc. (AMGN)

image159

Amgen (AMGN) Presents At Oppenheimer's 29th Annual Healthcare Conference - Slideshow

Apr. 1, 2019 1:34 PM ET | About: Amgen Inc. (AMGN) 

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

image160

Bausch + Lomb Announces The U.S. Launch Of LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery

Tue April 2, 2019 7:00 AM|PR Newswire|About: BHC

Shipments to U.S. Pharmaceutical Distributors Begin

BRIDGEWATER, N.J., April 2, 2019 /PRNewswire

Johnson & Johnson (JNJ)

image161

Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc.

Mon April 1, 2019 4:30 PM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., April 1, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash.

Rubraca® (rucaparib)

Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019

Tue April 2, 2019 8:30 AM|Business Wire|About: CLVS 


 https://www.rubraca.com/ 


 https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2019/Clovis-Oncology-Announces-Interim-Results-from-Rubraca-rucaparib-Phase-2-Study-in-Advanced-Pancreatic-Cancer-and-Nonclinical-Data-in-Multiple-Solid-Tumor-Types-for-Rucaparib-and-Lucitanib-Presented-at-AACR-2019/default.aspx 

seeking biotech alpha April 2019 insight

KEYTRUDA® (pembrolizumab)

image162

Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

Mon April 1, 2019 6:55 AM|Business Wire|About: MRK

KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK),

MEK 1/2 inhibitor selumetinib.

image163

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

Mon April 1, 2019 6:30 AM|Business Wire|About: MRK

Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas

Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck (MRK)

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck


ALKS 3831 (olanzapine/samidorphan)

image164

Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society

  • Mon April 1, 2019 7:00 AM|PR Newswire|About: ALKS
  • -- Poster Presentations to Highlight New Data on ARISTADA® and ALKS 3831 --

PR Newswire

DUBLIN, April 1, 2019 /PRNewswire/ -- Alkermes plc (ALKS

Bausch Health Companies Inc. (BHC) and UCLA's Technology Development Group

Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis

Mon April 1, 2019 7:00 AM|PR Newswire|About: BHC

Investigational Treatment Demonstrated Promising Results in Preclinical Studies

BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/

ADXS-PSA, Listeria monocytogenes (Lm)-based immunotherapies, with KEYTRUDA® (pembrolizumab)

image165

ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

Mon April 1, 2019 8:00 AM|Business Wire|About: ADXS

Updated Results from Phase 1/2 Study to be Presented Today at the AACR Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (ADXS)


 https://www.advaxis.com/clinical-trials/ 

investigational subcutaneous (SC) formulation of vedolizumab -Entyvio® (vedolizumab)

image166

European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease

April 1, 2019 Osaka, JAPAN

  • Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab
  • Vedolizumab set to be the only maintenance therapy to offer the option of intravenous or subcutaneous formulations across ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”)

seeking biotech alpha March 2019 insight

tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer

image168

Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Fri March 29, 2019 8:00 AM|Business Wire|About: SGEN

-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.-

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) (Nasdaq:SGEN) 


 http://www.seattlegenetics.com/pipeline/tisotumab-vedotin 


 http://www.genmab.com/product-pipeline/products-in-development/humax-tf-adc 

Viking Therapeutics, Inc. (VKTX)

image170

Viking Therapeutics to Participate in Upcoming Investor Conferences

Thu March 28, 2019 7:30 AM|PR Newswire|About: VKTX

SAN DIEGO, March 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX

seeking biotech alpha March 2019 insight

VY-AADC, an investigational gene therapy treatment for Parkinson’s disease

image174

Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology

Thu March 28, 2019 4:15 PM|GlobeNewswire|About: NBIX, VYGR

SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR


 Voyager Therapeutics, Inc. (VYGR)  

 https://www.voyagertherapeutics.com/  

HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)]

image175

Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults

Thu March 28, 2019 4:05 PM|GlobeNewswire|About: DVAX

BERKELEY, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX)


 http://www.dynavax.com/our-pipeline/ 

Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis

image176

 Basel, March 27, 2019   Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease

Mar 27, 2019

  • Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1]
     
  • Up to 80% of patients with relapsing remitting MS (RRMS) will develop SPMS[2]; Mayzent addresses a critical unmet need for RRMS patients in transition and those with active SPMS who have transitioned 
     
  • Approval is based on the Phase III EXPAND trial, the largest controlled clinical study of SPMS patients, showing Mayzent significantly reduced the risk of disease progression, including impact on physical disability and cognitive decline[3]
     
  • Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS), RRMS and active SPMS, with most patients not requiring a first dose observation

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China

image177

AstraZeneca leads in the development of a new International Life Science Innovation Park in China

PUBLISHED27 March 2019 


 Cluster to be built by the Wuxi municipal government and Wuxi High-tech District

seeking biotech alpha March 2019 insight

35 Abstracts Across NASH, PSC and Viral Hepatitis Commitment to Advancing Liver Disease Research

image180

Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019

Wed March 27, 2019 6:06 AM|Business Wire|About: GILD 

ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY

image181

Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in the U.S.

Wed March 27, 2019 4:49 PM|PR Newswire|About: JNJPR Newswire

JACKSONVILLE, Fla., March 27, 2019 /PRNewswire/ -- Johnson & Johnson Vision 

Casimersen (SRP-4045)

image182

Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study

Thu March 28, 2019 8:30 AM|GlobeNewswire|About: SRPT 

INVOKANA® (canagliflozin)

image183

 Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA®(canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

If approved, INVOKANA® will be the first and only therapy in nearly 20 years indicated to reduce the risk of end-stage kidney disease when added to current standard of care

Submission is based on data from the landmark Phase 3 CREDENCE renal outcomes study, which stopped early for positive efficacy findings

Raritan, N.J., March 28, 2019 

Seattle Genetics and Astellas reports positive data from EV-201

image184

Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin

Thu March 28, 2019 7:00 AM|Business Wire|About: SGEN

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN)


 http://www.seattlegenetics.com/pipeline/enfortumab-vedotin 


 https://seekingalpha.com/pr/17457684-seattle-genetics-astellas-announce-positive-topline-results-pivotal-trial-enfortumab-vedotin 

seeking biotech alpha March 2019 insight

Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF)

image185

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Tue March 26, 2019 8:30 AM|Business Wire|About: GILD 


 https://www.biktarvy.com/ 

Allergan plc (AGN) today announced it has completed the acquisition of Envy Medical, Inc.,

image187

Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio

Tue March 26, 2019 9:00 AM|PR Newswire|About: AGNPR Newswire

DUBLIN, March 26, 2019 /PRNewswire/ -- Allergan plc (AGN)

(etafilcon A with 0.019 mg ketotifen)

image188

Johnson & Johnson Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results

Tue March 26, 2019 8:00 AM|PR Newswire|About: JNJPR Newswire

JACKSONVILLE, Fla., March 26, 2019 /PRNewswire/ -- Johnson & Johnson 

Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC)

image189

Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer

Mon March 25, 2019 4:15 PM|Business Wire|About: VCYT 


 https://www.veracyte.com/our-products 

oral semaglutide 3 mg, 7 mg and 14 mg

image190

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Sat March 23, 2019 2:00 PM|PR Newswire|About: NONOF, NVO

NEW ORLEANS, March 23, 2019 /PRNewswire/ 

seeking biotech alpha March 2019 insight

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

image193

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Mon March 25, 2019 4:30 PM|Business Wire|About: CELG

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG)

Bria-IMT™, with KEYTRUDA®

image195

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

Tue March 26, 2019 6:30 AM|GlobeNewswire|About: BCTXF, MRK 


 https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf 

TriGrid® Delivery System.

image196

Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform

Tue March 26, 2019 7:00 AM|Business Wire|About: AZN

SAN DIEGO--(BUSINESS WIRE)-- Ichor® Medical Systems, Inc. (Ichor) 


 TriGrid® Delivery System


seeking biotech alpha March 2019 insight

MAVIRET™ (glecaprevir/pibrentasvir tablets)

image197

 British Columbia PharmaCare Lists AbbVie's Hepatitis C Treatment MAVIRET™ on its Formulary

Fri March 22, 2019 10:29 AM|Canada Newswire|About: ABBV 

DARZALEX (daratumumab), combined w/Celgene's (CELG) REVLIMID (lenalidomide)&dexamethasone

image198

J&J files European marketing application for expanded use of Darzalex

Mar. 22, 2019 8:22 AM ET|About: Celgene Corporation (CELG)|By: , SA News Editor 

Phase 1 study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy

image200

Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program

Mon March 25, 2019 7:30 AM|GlobeNewswire|About: SRPT 

Providence Cancer Institute and Galectin Therapeutics Inc. (GALT)

image201

Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

Fri March 22, 2019 10:19 AM|GlobeNewswire|About: GALT

NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (GALT)

seeking biotech alpha March 2019 insight

Phase IIa combination study of Bria-IMT™ with KEYTRUDA® [ Merck (MRK)] in advanced breast cancer

image203

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

Wed March 20, 2019 4:05 PM|GlobeNewswire|About: BCTXF, MRK

BERKELEY, Calif. and VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTXF) ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF)

ABIOMED (NASDAQ:ABMD) discloses a 6% stake of 1,678,843 shares in ShockWave Medical (NASDAQ:SWAV),

Abiomed reports 6% stake in ShockWave Medical

Mar. 21, 2019 6:55 AM ET|About: ABIOMED, Inc. (ABMD)|By: , SA News Editor  


https://shockwavemedical.com/?country=United%20States

Viking Therapeutics, Inc. (VKTX)

image205

Viking Therapeutics (VKTX) Investor Presentation - Slideshow

Mar. 21, 2019 3:12 PM ET | About: Viking Therapeutics, Inc. (VKTX) 

Sorrento Therapeutics, Inc. (SRNE)

image206

Sorrento Therapeutics (SRNE) Presents At Oppenheimer 29th Annual Healthcare Conference - Slideshow

Mar. 21, 2019 2:29 PM ET|1 comment | About: Sorrento Therapeutics, Inc. (SRNE) 

seeking biotech alpha March 2019 insight

oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in pill form.

image208

Novo files two U.S. applications for oral semaglutide

Mar. 20, 2019 11:07 AM ET|About: Novo Nordisk A/S (NVO)|By: , SA News Editor  

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) & Eli Lilly (LLY)

image210

NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology

Wed March 20, 2019 8:45 AM|PR Newswire|About: LLY

PLYMOUTH MEETING, Pa. and INDIANAPOLIS, March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (LLY

seeking biotech alpha March 2019 insight

seeking biotech alpha March 2019 insight

BRAFTOVI® (encorafenib) in Combination w/ MEKTOVI® (binimetinib) & ERBITUX® (cetuximab) panitumumab

image218

BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer

Mon March 18, 2019 8:00 AM|PR Newswire|About: ARRY

BOULDER, Colo., March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY


https://www.braftovimektovi.com/

(sNDA) for AVYCAZ® (ceftazidime and avibactam)

image219

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Mon March 18, 2019 7:30 AM|PR Newswire|About: AGNPR Newswire

DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (AGN)

(VENCLEXTA®/VENCLYXTO®) for the investigational treatment of multiple myeloma

image221

AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

Tue March 19, 2019 8:45 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (ABBV)


https://www.venclexta.com/

saracatinib an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

image222

US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis  

18 March 2019 07:00 GMT

 AstraZeneca PLC (AZN) 

 

seeking biotech alpha March 2019 insight

Novocure (NVCR)

image225

 Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference

Mon March 18, 2019 7:30 AM|Business Wire|About: NVCR

ST. HELIER, Jersey--(BUSINESS WIRE)--

Novocure (NASDAQ:NVCR) 

Stryker acquires OrthoSpace, Ltd.

Stryker acquires OrthoSpace, Ltd.

03/14/2019

Kalamazoo, Michigan, March 14, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today it has completed the acquisition of OrthoSpace, Ltd., a privately held company founded in 2009 and headquartered in Caesarea, Israel, in an all cash transaction for an upfront payment of $110 million and future milestone payments of up to an additional $110 million.

seeking biotech alpha March 2019 insight

OPSUMIT® (macitentan)

image230

 Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)

Fri March 15, 2019 9:00 AM|PR Newswire|About: JNJPR Newswire

SOUTH SAN FRANCISCO, Calif. and ALLSCHWIL, Switzerland, March 15, 2019 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)


https://www1.actelion.us/us/products/index.page?

da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults.

image231

U.S. FDA Clears da Vinci SP for Certain Transoral Otolaryngology Procedures

Fri March 15, 2019 1:36 PM|GlobeNewswire|About: ISRGGlobeNewswire

SUNNYVALE, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Intuitive (ISRG)


https://www.intuitive.com/en-us/products-and-services/da-vinci/systems/sp

MabThera (rituximab) for a rare autoimmune disease

image232

 

Basel, 15 March 2019

European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease

  • MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease in more than 60 years
  • PV is a rare and potentially life-threatening blistering condition which can cause severe pain and disfigurement
  • MabThera is now approved in Europe to treat four autoimmune diseases

Roche (SIX: RO, ROG; OTCQX: RHHBY)

seeking biotech alpha March 2019 insight

WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC)

image233

Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Wed March 13, 2019 7:00 AM|PR Newswire|About: BSXPR Newswire

MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX

Hemlibra® (emicizumab)

image236

Chugai’s Hemlibra Receives Approval for Severe Hemophilia A Without Factor VIII Inhibitors from the European Commission

Thu March 14, 2019 2:00 AM|Business Wire|About: CHGCY, RHHBY 

Venovo™ venous stent

image238

BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

Thu March 14, 2019 6:59 AM|PR Newswire|About: BDXPR Newswire

FRANKLIN LAKES, N.J., March 14, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX)

seeking biotech alpha March 2019 insight

Regeneron Pharmaceuticals, Inc. (REGN) and Society for Science & the Public

image244

Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem

Tue March 12, 2019 9:56 PM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and WASHINGTON, March 12, 2019 /PRNewswire/

seeking biotech alpha March 2019 insight

Dupixent® (dupilumab) for adolescent patients 12 to 17 with moderate-to-severe atopic dermatitis

image249

FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

Mon March 11, 2019 3:45 PM|PR Newswire|About: REGN, SNY

* In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin

PR Newswire

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/

Station B

image250

 

Microsoft researchers have spent years studying those underlying processes and learning how to influence them. Now they are launching collaborations with Princeton University and UK-based companies Oxford Biomedica and Synthace to develop and test an integrated platform that’s designed to help other companies and research teams perform that work more reliably. The goal: To reduce the amount of trial and error required to make beneficial scientific breakthroughs and enable companies and academic researchers already established in the field to operate more efficiently and cost-effectively.

The project, called Station B, aims to develop an end-to-end platform — including a software stack, a means to automate lab experiments and machine learning methods that run in the cloud on Microsoft Azure — to help scientists more efficiently and predictably channel the power of life’s ultimate information processing machines: living cells.

 

Jennifer Langston

Mar 11, 2019

CAMBRIDGE, United Kingdom – In recent years, companies have figured out how to engineer bacteria to make cement, helping reduce the pollution involved in traditional manufacturing. Using more advanced techniques, scientists have even programmed patients’ immune cells to recognize and kill leukemia cells, giving children who had virtually no chance of survival years of prolonged life.

seeking biotech alpha March 2019 insight

Medtronic plc (MDT)

image253

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2019

Fri March 8, 2019 4:30 PM|InPublic US|About: MDT


Board Authorizes $6 Billion for Share Repurchases

DUBLIN - March 8, 2018 - The board of directors of Medtronic plc (MDT)

ubrogepant for the acute treatment of migraine in adults.

image255

Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine

Mon March 11, 2019 7:30 AM|PR Newswire|About: AGN

Allergan Continues to Expand Its Leading Migraine Portfolio Across the Spectrum of the Disease from Episodic to Chronic -

PR Newswire

DUBLIN, March 11, 2019 /PRNewswire/ -- Allergan plc (AGN)

seeking biotech alpha March 2019 insight

GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function

image257

 Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies

Thu March 7, 2019 5:30 PM|Business Wire|About: GILD

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)